• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

整合分子亚型和 CD8 T 细胞浸润以预测肌层浸润性膀胱癌的治疗反应和生存。

Integrating molecular subtype and CD8 T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer.

机构信息

Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.

NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.

出版信息

Cancer Immunol Immunother. 2024 Mar 2;73(4):66. doi: 10.1007/s00262-024-03651-3.

DOI:10.1007/s00262-024-03651-3
PMID:38430246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10908619/
Abstract

BACKGROUND

Luminal and Basal are the primary intrinsic subtypes of muscle-invasive bladder cancer (MIBC). The presence of CD8 T cells infiltration holds significant immunological relevance, potentially influencing the efficacy of antitumor responses. This study aims to synergize the influence of molecular subtypes and CD8 T cells infiltration in MIBC.

METHODS

This study included 889 patients with MIBC from Zhongshan Hospital, The Cancer Genome Atlas, IMvigor210 and NCT03179943 cohorts. We classified the patients into four distinct groups, based on the interplay of molecular subtypes and CD8 T cells and probed into the clinical implications of these subgroups in MIBC.

RESULTS

Among patients with Luminal-CD8T tumors, the confluence of elevated tumor mutational burden and PD-L1 expression correlated with a heightened potential for positive responses to immunotherapy. In contrast, patients featured by Luminal-CD8T displayed a proclivity for deriving clinical advantages from innovative targeted interventions. The Basal-CD8T subgroup exhibited the least favorable three-year overall survival outcome, whereas their Basal-CD8T counterparts exhibited a heightened responsiveness to chemotherapy.

CONCLUSIONS

We emphasized the significant role of immune-molecular subtypes in shaping therapeutic approaches for MIBC. This insight establishes a foundation to refine the process of selecting subtype-specific treatments, thereby advancing personalized interventions for patients.

摘要

背景

腔面型和基底型是肌层浸润性膀胱癌(MIBC)的主要内在亚型。CD8 T 细胞浸润的存在具有重要的免疫学意义,可能影响抗肿瘤反应的疗效。本研究旨在综合分子亚型和 MIBC 中 CD8 T 细胞浸润的影响。

方法

本研究纳入了来自中山医院、癌症基因组图谱、IMvigor210 和 NCT03179943 队列的 889 例 MIBC 患者。我们根据分子亚型和 CD8 T 细胞的相互作用将患者分为四个不同的组,并探讨了这些亚组在 MIBC 中的临床意义。

结果

在腔面型-CD8T 肿瘤患者中,肿瘤突变负担和 PD-L1 表达升高的汇合与对免疫治疗产生积极反应的潜力增加相关。相比之下,表现为腔面型-CD8T 的患者更倾向于从创新的靶向干预中获得临床优势。基底型-CD8T 亚组的三年总生存率最差,而他们的基底型-CD8T 对应物对化疗的反应性更高。

结论

我们强调了免疫-分子亚型在制定 MIBC 治疗方法中的重要作用。这一见解为细化选择特定亚型治疗的过程奠定了基础,从而推进了针对患者的个性化干预措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/4b38f2e09650/262_2024_3651_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/a0ef362ade7a/262_2024_3651_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/6ea0e4636800/262_2024_3651_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/1173a4cd6e0a/262_2024_3651_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/3458f43d12ff/262_2024_3651_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/5ffa49ed3b8a/262_2024_3651_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/4b38f2e09650/262_2024_3651_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/a0ef362ade7a/262_2024_3651_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/6ea0e4636800/262_2024_3651_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/1173a4cd6e0a/262_2024_3651_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/3458f43d12ff/262_2024_3651_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/5ffa49ed3b8a/262_2024_3651_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5016/10992679/4b38f2e09650/262_2024_3651_Fig6_HTML.jpg

相似文献

1
Integrating molecular subtype and CD8 T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer.整合分子亚型和 CD8 T 细胞浸润以预测肌层浸润性膀胱癌的治疗反应和生存。
Cancer Immunol Immunother. 2024 Mar 2;73(4):66. doi: 10.1007/s00262-024-03651-3.
2
Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.VISTA 的免疫失活可预测肌层浸润性膀胱癌的临床结局和治疗获益。
BMC Cancer. 2023 Jul 14;23(1):661. doi: 10.1186/s12885-023-11157-x.
3
Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.肿瘤相关巨噬细胞浸润和极化预测肌层浸润性膀胱癌的预后和治疗获益。
Cancer Immunol Immunother. 2022 Jun;71(6):1497-1506. doi: 10.1007/s00262-021-03098-w. Epub 2021 Oct 30.
4
Integration of CD4 T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer.CD4 T 细胞与分子亚型的整合预测 PD-L1 阻断在肌层浸润性膀胱癌中的获益。
Cancer Sci. 2024 Apr;115(4):1306-1316. doi: 10.1111/cas.16119. Epub 2024 Feb 25.
5
Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 CD8 T cell abundance.肿瘤内CXCR5阳性CD8 T细胞丰富的肌层浸润性膀胱癌患者的良好预后亚型的鉴定与验证
Oncoimmunology. 2020 Aug 28;9(1):1810489. doi: 10.1080/2162402X.2020.1810489.
6
Stromal LAG-3 cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture.基质 LAG-3 细胞浸润定义了具有免疫逃避结构的预后不良的肌肉浸润性膀胱癌亚型。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000651.
7
Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.表达白细胞介素-10 的免疫抑制性肿瘤相关巨噬细胞赋予肌层浸润性膀胱癌患者不良预后和治疗脆弱性。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003416.
8
Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.通过引入肿瘤突变负担、CD8+T 细胞和分子亚型定义肌肉浸润性膀胱癌免疫亚型。
Hereditas. 2021 Jan 2;158(1):1. doi: 10.1186/s41065-020-00165-7.
9
Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.神经纤毛蛋白-1 的免疫失活可预测肌层浸润性膀胱癌的临床结局和治疗获益。
Cancer Immunol Immunother. 2022 Sep;71(9):2117-2126. doi: 10.1007/s00262-022-03153-0. Epub 2022 Jan 18.
10
Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.潜伏期相关肽鉴定出具有不良预后的治疗抵抗性肌肉浸润性膀胱癌。
Cancer Immunol Immunother. 2022 Feb;71(2):301-310. doi: 10.1007/s00262-021-02987-4. Epub 2021 Jun 21.

引用本文的文献

1
Role of the tumor microenvironment in promoting treatment resistance in urothelial carcinoma (Review).肿瘤微环境在促进尿路上皮癌治疗抵抗中的作用(综述)
Mol Med Rep. 2025 Nov;32(5). doi: 10.3892/mmr.2025.13658. Epub 2025 Aug 24.
2
Development and validation of interpretable machine learning models to predict distant metastasis and prognosis of muscle-invasive bladder cancer patients.用于预测肌层浸润性膀胱癌患者远处转移和预后的可解释机器学习模型的开发与验证
Sci Rep. 2025 Apr 6;15(1):11795. doi: 10.1038/s41598-025-96089-1.
3
Cuproptosis-related signature predicts prognosis and indicates tumor immune infiltration in bladder cancer.

本文引用的文献

1
Dynamic CD8 T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.在转移性淋巴结中,癌症免疫治疗在人体区域淋巴结中诱导的动态 CD8 T 细胞反应被打乱。
Cell. 2023 Mar 16;186(6):1127-1143.e18. doi: 10.1016/j.cell.2023.02.021.
2
Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma.胰腺导管腺癌根治性切除术后肿瘤相关 N1/N2 中性粒细胞可塑性的预后价值。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005798.
3
Interferon-dependent SLC14A1 cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer.
铜死亡相关特征预测膀胱癌预后并指示肿瘤免疫浸润
Transl Androl Urol. 2024 Oct 31;13(10):2280-2293. doi: 10.21037/tau-24-456. Epub 2024 Oct 28.
4
Tumor hypoxia in immune infiltration and prognosis of bladder cancer.肿瘤缺氧在膀胱癌免疫浸润及预后中的作用
Transl Cancer Res. 2024 Jul 31;13(7):3273-3284. doi: 10.21037/tcr-23-2375. Epub 2024 Jul 26.
干扰素依赖的 SLC14A1 癌症相关成纤维细胞通过 WNT5A 在膀胱癌中促进癌症干性。
Cancer Cell. 2022 Dec 12;40(12):1550-1565.e7. doi: 10.1016/j.ccell.2022.11.005. Epub 2022 Dec 1.
4
APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases.APOBEC 介导的突变是膀胱癌患者预后和免疫治疗的有利预测指标:来自泛癌症分析和多个数据库的证据。
Theranostics. 2022 May 16;12(9):4181-4199. doi: 10.7150/thno.73235. eCollection 2022.
5
CD103CD8 tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer.CD103CD8 组织驻留记忆 T 细胞浸润预测肌肉浸润性膀胱癌的临床结局和辅助治疗获益。
Br J Cancer. 2022 Jun;126(11):1581-1588. doi: 10.1038/s41416-022-01725-6. Epub 2022 Feb 14.
6
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.2021 年更新版欧洲泌尿外科学会转移性尿路上皮癌临床实践指南。
Eur Urol. 2022 Jan;81(1):95-103. doi: 10.1016/j.eururo.2021.09.026. Epub 2021 Nov 3.
7
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.泛癌种保守的微环境亚型可预测免疫治疗的反应。
Cancer Cell. 2021 Jun 14;39(6):845-865.e7. doi: 10.1016/j.ccell.2021.04.014. Epub 2021 May 20.
8
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.TROPHY-U-01 研究:在铂类化疗和检查点抑制剂治疗后进展的转移性尿路上皮癌患者中 sacituzumab govitecan 的 II 期开放标签研究。
J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30.
9
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.III 期黑色素瘤中 OpACIN-neo 和 OpACIN 新辅助免疫治疗试验的生存和生物标志物分析。
Nat Med. 2021 Feb;27(2):256-263. doi: 10.1038/s41591-020-01211-7. Epub 2021 Feb 8.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.